CELS Forum: Practical Advice for Americans Investing in Canadian Life Science Companies
Jun 
30
 | 
10:30am
Ticket Sales Are Closed
Text goes here
X

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining

9:30am–10:00am

Registration Opens, Networking & Introductions

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Ticket Sales Are Closed
Text goes here
X
9:30am
–
2:00pm
July 
22
, 
2018

CELS Forum: Practical Advice for Americans Investing in Canadian Life Science Companies

10:30am
–
1:00pm
October 
17
–
October 
24
CELS Forum: Practical Advice for Americans Investing in Canadian Life Science Companies
3:00pm
–
5:30pm

Program Overview

You are a U.S.-based investor seeking exceptional life science therapeutics and technologies.  Canada's life science community features world-class technologies and technical professionals, that are important contributors to the U.S. and global markets. However, you may be reluctant to invest directly outside the U.S. because of various uncertainties. To address these concerns, this session brings together a panel of experts from key disciplines to highlight paths/options to tap into attractive investments across the US/Canada border.  

 

Join us to gain factual insights on stress-free strategies to invest in Canadian companies.  


Who should attend: U.S. investors and those interested in learning about investor challenges and solutions when making cross-border deals.


Speakers

Mike Futrell

City Manager

City of South San Francisco

 Mike Futrell began serving as City Manager of South San Francisco, California, in April 2014, bringing broad executive experience in local, state and federal government. He was Chief Administrative Officer for the City of Baton Rouge, Louisiana; served on staff in the United States Senate; and was an elected member of the Louisiana House of Representatives and of the Baton Rouge City Council. He served as a submarine officer in the U.S. Navy and rose to the rank of Navy Captain in the Navy Reserves. He previously practiced law with a private firm and was Executive Vice President of a public utility company in Hawaii.

Mike holds a bachelor's degree in Business/Public Administration and a Juris Doctorate degree from Louisiana State University, a Masters in Business Administration (MBA) from the University of Massachusetts-Amherst, and completed the Stanford Graduate School of Business Learn-Engage-Accelerate-Disrupt (LEAD) Certificate program in Corporate Innovation. 

Kinkead Reiling

CEO and Founder

Bonneville Labs

Kinkead Reiling, PhD is founder and CEO of Bonneville Labs, which provided lab space and operations for biotechnology companies. From 2012 to 2016, Dr Reiling advised multiple biotechnology companies and invested in and developed real estate.

 

From 2003 to 2011, Dr Reiling co-founded and helped to grow the industrial biology company Amyris producing Biofuels and Bio-Chemicals. Prior to Amyris, he worked as a post-doctoral scholar in the UC Berkley Chemical Engineering Department developing microbial production systems for Anti-Malarial and Anti-Cancer therapeutic compounds.


He completed his doctoral studies at UC, San Francisco in BioPhysics and his Master’s degree in Applied Physics from Columbia University.


Panelists

TO BE ANNOUNCED. STAY TUNED!

Panelists

Hatim Chraibi (MODERATOR)

Co-founder

The SPIRE Advisory Group

Hatim Chraibi has more than 18 years experience in the medical device industry in both upstream and downstream capacities globally. Mr. Chraibi received a bachelor degree in Finance from the University of San Francisco, and an MBA from McGill University (Exchange program at the Luigi Bocconi University in Milan, Italy).


Before co-founding the SPIRE Advisory Group where he acts as Managing Director, Hatim has had tenures at Philips Medical Systems, Covidien and other smaller medical device companies. He has built various global organizations and contributed significantly to their international sales. SPIRE Advisory Group works with international start-ups and government organizations to provide guidance, mentoring and funding in the Bay Area ecosystem.


Mr. Chraibi has an intimate expertise of the Medical device industry worldwide, has worked in various countries and is fluent in 5 languages.


His areas of interest and expertise include start-up mentoring in product definition/positioning, market research, key opinion leaders’ engagement, product positioning and global distribution. Hatim is also a strategic advisor for various medical device and diagnostic companies.    

Marwan Berrada-Sounni

Executive-in-Residence

ShifaMed

Marwan is currently an Executive-in-Residence at ShifaMed incubating and building the next portfolio company. Previously, he was at the Cleveland Clinic Foundation as Sr. Director, Product Development with responsibilities to resolve clinical unmet needs within the Heart and Vascular Institute and spinning out either projects or companies. Marwan was also part of the commercialization funding committee within the Global Cardiovascular Innovation Center at the Cleveland Clinic, which an economic development and investment fund for the state of Ohio. Product expertise has been in percutaneous therapies such as electrophysiology, structural heart, cardiovascular and endovascular devices, in addition to product commercialization of orthopedic implants. Through his engineering and business backgrounds, Marwan is experienced in leading both traditional and virtual R&D teams throughout the entire development life-cycle including 510k and PMA regulatory tracks. He has held various engineering, managerial, and executive management positions in companies such as Microvena, ev3, CryoCath Technologies, Bavaria Medical Technologies, Vascular NanoTransfer, OligoMedic, NexStep Medical, and MitraCore. Currently Marwan holds nine (9) patents in medical devices, and more then thirteen (13) patent applications. Marwan is a serial entrepreneur involved in multiple start-up either as co-founder or advisor. He holds a Bachelor’s and Master’s degree in Mechanical Engineering from the University of Minnesota and an MBA in Finance from McGill University.

 

Pavan Dhillon

Canadian Immigration Attorney

Dhillon Immigration Law

Pavan Dhillon is the Founder and Principal Attorney at Dhillon Immigration Law, a boutique law firm specializing in Canadian business immigration. Based in San Francisco, Pavan has cultivated a unique expertise in cross border business immigration and provides compliance-driven, in-bound Canadian immigration solutions to companies and individuals.


For over ten years, Pavan has served as trusted advisor to global corporations, regional companies and start-ups with a cross-border presence. Oftentimes, she devises strategies for these companies to attract or retain global talent within North America by leveraging Canada’s generous immigration programs for high-skilled workers. With respect to short-term work authorization, she guides employees and executives in avoiding the potential pitfalls of cross-border business travel.


Prior to launching her boutique practice, Pavan led the Canadian immigration practice at a global law firm. She is originally from Vancouver, British Columbia. She is admitted to practice law in British Columbia and New York.

Joseph Garcia

Partner

Blake, Cassels & Graydon LLP

Joseph's practice focuses on corporate finance and mergers and acquisitions. He advises public and private companies, investment dealers, venture capital and private equity funds and acts as independent counsel to boards of directors. Joseph has extensive experience advising on all types of merger and acquisition and corporate finance transactions including public and private equity and debt financings, take-over and issuer bids, share and asset acquisitions and divestitures, and regulatory and stock exchange compliance work.

 

Prior to his career in law, Joseph worked in corporate finance with a national investment bank and in clinical research with a multinational pharmaceutical company.

 

Joseph has lectured extensively on corporate governance and advanced securities law topics. He has chaired The Continuing Legal Education Society of British Columbia Corporate Governance courses in 2011, 2013, 2015 and 2017, and participated in the advanced securities law courses from 2007-2009, 2011 and from 2013-2015.

 

Joseph is a director of Genome BC and chair of its Audit Committee. He is a director emeritus of LifeSciences BC and a member of its Finance Committee. He is also a director of the Canadian Glycomics Network and a member of the BIOTECanada Legal Affairs Advisory Board, the Canadian Bar Association and the American Bar Association.

 

 

Sam Ifergan


Founder & Managing Partner

iGan Partners

Sam is the Founder and Managing Partner of iGan Partners and has over 20 years of entrepreneurial, technology and venture capital experience. Sam founded iGan Partners in 2013 and is now the largest healthcare venture capital investor in Canada. Sam is actively involved in evaluating, structuring and executing iGan's investments.  Collectively iGan has supported the creation of over 20 successful medical device and tech companies in Canada. 


Sam works very closely with portfolio companies and is actively involved in their commercialization.  He serves as the Chairman of eSight and MolecuLight and sits on the board of seven other MedTech companies. Prior to founding IGan Partners, Sam co-founded and exited several tech companies including Visual Sonics, Tri-Link Technologies and Brighter Minds.

 
Sam holds a Bachelor of Electrical Engineering from McGill University and an MBA from the John Molson School of Business. 

Paul Russo

Founder & CEO

Kyto Technology and Life Science, Inc.

Dr. Paul Russo is the Founder and CEO of Kyto Technology and Life Science, Inc., a public entity actively investing in start-ups (www.kytotech.com ).  He is also the Founder and Chairman of GEO Semiconductor, a world-leading supplier of automotive camera processors with over 200 design wins. He sits on several start-up boards in the US and Canada.  He is a former board member of ATI technologies through its acquisition by AMD and is active in both the Band of Angels and the Keiretsu Forum, and has recently joined the Silicon Catalyst Angels. Before GEO, Dr. Russo started Silicon Optix and Genesis Microchip. The latter dominated the chip market for flat computer displays and had a hugely successful NASDAQ IPO in 1998.  Prior to the above, he served as GM of GE’s Microelectronics Center, Manager of the GE Industrial Electronics Laboratory. 


Prior to GE, he was at RCA Laboratories, where he helped develop the world’s first CMOS microprocessor, and the first uses of these devices in video games, auto engine control, and global communications. 

 

He received his B. Eng. in from McGill and his MSc and PhD in EECS from UC Berkeley.  He holds 8 patents, has published extensively, and is the recipient of numerous awards, including the IEEE Centennial Medal and the Tech Pioneer Award from the World Economic Forum. 

EVENT PARTNER


You are a U.S.-based investor seeking exceptional life science therapeutics and technologies.  Canada's life science community features world-class technologies and technical professionals, that are important contributors to the U.S. and global markets. However, you may be reluctant to invest directly outside the U.S. because of various uncertainties. To address these concerns, this session brings together a panel of experts from key disciplines to highlight paths/options to tap into attractive investments across the US/Canada border.  

 

Join us to gain factual insights on stress-free strategies to invest in Canadian companies.  


Who should attend: U.S. investors and those interested in learning about investor challenges and solutions when making cross-border deals.

#Meetwith...JJDCBayArea

Vijay Murthy

]Principal, Venture Investments

Johnson & Johnson Innovation, JJDC Inc.

Vijay is a Principal of Venture Investments at Johnson & Johnson Innovation, JJDC. Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in California. Vijay focuses on venture investments in biotechnology, pharmaceuticals, and diagnostics.


Prior to joining JJDC, Vijay was a Director of Ventures & Early-Stage Collaborations at AbbVie, where he focused on venture investments and preclinical business development transactions. Prior to AbbVie, Vijay was co-founder and CEO of an early-stage peptide manufacturing company, and an independent consultant to several top-tier life sciences venture capital firms and biopharmaceutical companies. Previously, Vijay led business development at Enlight Biosciences, a seed-stage venture creation firm founded by PureTech Health and partnered with 7 major biopharmaceutical companies. He started his business career as a strategy consultant at the Boston Consulting Group (BCG).

 

Vijay earned an AM and a PhD in biophysical chemistry from Harvard University, and a BS in chemistry with highest honors and highest distinction from the University of North Carolina at Chapel Hill.

#Meetwith...JJDCBayArea

Hosted by Your Company

Agenda

3:00 pm - 3:30 pm

Registration, Networking and Introductions

3:30 pm - 4:30 pm

Panel Discussion 

 **Webinar Begins**

4:30 pm - 5:00 pm

Audience Q & A 

5:00 pm - 5:30 pm

Networking & Refreshments

**Webinar Closes**

Speakers

Nilesh Kumar

Partner, Novo Ventures

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Dr. Arjun Desai

Chief Operating Officer, JLabs

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Diana Rhie

Business Op. Lead, JLabs

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Shamin Dewsi

Business Op. Lead, JLabs

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Tom Luby

Head of JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Danielle Barreto

Admin. Coordinator, JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

Erika Kula

Sourcing Innovation , JLabs

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

JLABS Event Partners

PARTNERS



 

JLABS on Twitter

Ticket Sales Are Closed
Text goes here
X

Text Block #1

Starting your own business and picking the right niche in no time

The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information presented. By subscribing and participating in this event, you agree you have read and accepted this. 

RSVPs are closed
Submit
Text goes here
X
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Ticket
$0000
Ticket description
Day Month 0th 0:00pm
Day Month 0th 0:00pm
100 remaining
Tickets closed
Submit
Text goes here
X
[confirmation_headline]
[confirmation_messaging]
Add to Calendar
Text goes here
X
[confirmation_headline]
[confirmation_messaging]
Add to Calendar
Text goes here
X
CONTACT THE ORGANIZER
Google   Outlook   iCal   Yahoo
Sorry, ticket sales have closed.